This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ornidazole is a nitroimidazole agent indicated in the treatment of infections such as trichomoniasis, amebiasis, and giardiasis.
- Generic Name
- Ornidazole
- DrugBank Accession Number
- DB13026
- Background
Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Ornidazole (DB13026)
- Weight
- Average: 219.63
Monoisotopic: 219.0410689 - Chemical Formula
- C7H10ClN3O3
- Synonyms
- ornidazol
- Ornidazole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Amebiasis •••••••••••• Treatment of Anaerobic bacterial infection •••••••••••• Used in combination to treat Chlamydial infections Combination Product in combination with: Ciprofloxacin (DB00537) •••••••••••• ••••••• ••••••• •••••• Treatment of Gastrointestinal infections caused by entamoeba histolytica •••••••••••• Treatment of Giardiasis •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAtracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Ornidazole. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Ornidazole. Botulinum toxin type A The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Ornidazole. Cisatracurium The therapeutic efficacy of Cisatracurium can be increased when used in combination with Ornidazole. DaxibotulinumtoxinA The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Ornidazole. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ORCIPOL 500 MG/500 MG FILM TABLET, 10 ADET Ornidazole (500 mg) + Ciprofloxacin (500 mg) Tablet, film coated Oral World Medicine Ilac San. Ve Tic. a.s. 2020-08-14 2018-07-30 Turkey 
ORCIPOL 500 MG/500 MG FILM TABLET, 14 ADET Ornidazole (500 mg) + Ciprofloxacin (500 mg) Tablet, film coated Oral World Medicine Ilac San. Ve Tic. a.s. 2020-08-14 2018-07-30 Turkey ORCIPOL 500 MG/500 MG FILM TABLET, 20 ADET Ornidazole (500 mg) + Ciprofloxacin (500 mg) Tablet, film coated Oral World Medicine Ilac San. Ve Tic. a.s. 2014-06-27 2018-07-30 Turkey ORCIPOL 500 MG/500 MG FILM TABLET, 28 ADET Ornidazole (500 mg) + Ciprofloxacin (500 mg) Tablet, film coated Oral World Medicine Ilac San. Ve Tic. a.s. 2020-08-14 2018-07-30 Turkey ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET Ornidazole (500 mg) + Ciprofloxacin (500 mg) Tablet, film coated Oral GENVEON İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 2018-07-30 Turkey - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ORNITOP 250 MG FILM TABLET, 20 ADET Ornidazole (250 mg) Tablet, film coated TOPRAK İLAÇ VE KİMYEVİ MADDELER SAN.VE TİC. A.Ş. 2020-07-21 Not applicable Turkey ORNITOP 500 MG FILM TABLET, 10 ADET Ornidazole (500 mg) Tablet, film coated TOPRAK İLAÇ VE KİMYEVİ MADDELER SAN.VE TİC. A.Ş. 2013-01-29 Not applicable Turkey
Categories
- ATC Codes
- G01AF06 — Ornidazole
- G01AF — Imidazole derivatives
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- J01XD — Imidazole derivatives
- J01X — OTHER ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- P01AB — Nitroimidazole derivatives
- P01A — AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
- P01 — ANTIPROTOZOALS
- P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Amebicides
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antiparasitic Agents
- Antiparasitic Products, Insecticides and Repellents
- Antiprotozoals
- Antitrichomonal Agents
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Imidazole Derivatives
- Imidazoles
- Nitro Compounds
- Nitroimidazole Derivatives
- Nitroimidazoles
- Radiation-Sensitizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Imidazoles
- Direct Parent
- Nitroimidazoles
- Alternative Parents
- 1,2,5-trisubstituted imidazoles / Nitroaromatic compounds / N-substituted imidazoles / Heteroaromatic compounds / Secondary alcohols / Chlorohydrins / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organic oxoazanium compounds / Organic oxides show 6 more
- Substituents
- 1,2,5-trisubstituted-imidazole / Alcohol / Alkyl chloride / Alkyl halide / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Chlorohydrin / Halohydrin show 20 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- C-nitro compound, secondary alcohol, imidazoles, organochlorine compound (CHEBI:75176)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 62XCK0G93T
- CAS number
- 16773-42-5
- InChI Key
- IPWKIXLWTCNBKN-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
- IUPAC Name
- 1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
- SMILES
- CC1=NC=C(N1CC(O)CCl)N(=O)=O
References
- General References
- TITCK Product Information: Bitazol (ornidazole) solution for infusion [Link]
- TITCK Product Information: Bitazol (ornidazole) film-coated tablets [Link]
- TITCK Product Information: Bitazol (ornidazole) vaginal tablets [Link]
- TITCK Product Information: Ornisasin (ornidazole/ciprofloxacin hydrochloride) film-coated tablets [Link]
- External Links
- PubChem Compound
- 28061
- PubChem Substance
- 347829160
- ChemSpider
- 26102
- 7701
- ChEBI
- 75176
- ChEMBL
- CHEMBL1449676
- Wikipedia
- Ornidazole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Elective Colorectal Surgery 1 3 Completed Prevention Rectal Cancer Surgery 1 3 Terminated Prevention Colon Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated 500 mg Tablet, film coated 250 mg Insert Vaginal 500 mg Injection, solution Intravenous 500 mg Insert Vaginal Solution Intravenous 500 mg/3ml Solution Parenteral 500 mg/3ml Injection, solution Intravenous 500 mg/3ml Tablet, film coated Oral Injection, solution Intravenous Tablet, coated Tablet Oral Solution Parenteral 1000 mg Injection Intravenous 500 mg/3ml Tablet Oral 500 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.34 mg/mL ALOGPS logP 0.37 ALOGPS logP 0.26 Chemaxon logS -1.8 ALOGPS pKa (Strongest Acidic) 13.89 Chemaxon pKa (Strongest Basic) 3.08 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 83.87 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 50.23 m3·mol-1 Chemaxon Polarizability 19.59 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS splash10-004i-3911000000-5b4872e026a447ba42bd MS/MS Spectrum - , positive LC-MS/MS splash10-00fr-0590000000-51e17e00bdee7b7e70f6 MS/MS Spectrum - , positive LC-MS/MS splash10-00fr-1590000000-10d4a11d06fa5ff22012 MS/MS Spectrum - , positive LC-MS/MS splash10-004i-3911000000-5b4872e026a447ba42bd Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 137.1045 predictedDeepCCS 1.0 (2019) [M+H]+ 140.93184 predictedDeepCCS 1.0 (2019) [M+Na]+ 150.26062 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 02:10 / Updated at June 12, 2021 10:54